依美昔單抗
化合物
依美昔單抗（INN：ecromeximab；開發代號：KW2871）是一種嵌合單株抗體，正在開發用於治療惡性黑色素瘤。[1][2]該藥物被用來針對轉移性黑色素瘤進行I期臨床試驗，[3]並在隨後與高劑量的干擾素α2b聯合進行了II期臨床試驗。[4][5]
| 單株抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | GD3神經節苷脂 |
| 臨床資料 | |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 292819-64-8  |
| ChemSpider |
|
| UNII | |
| 化學資訊 | |
| 摩爾質量 | 145255 g/mol |
該藥物由協和發酵工業株式會社開發。截至2015年12月，開發已停止。[6]
參考資料
編輯- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Ecromeximab （頁面存檔備份，存於互聯網檔案館）, American Medical Association.
- ^ Clinical trial number NCT00679289 for "Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Cutaneous Melanoma" at ClinicalTrials.gov
- ^ Forero, Andres; Shah, Jatin; Carlisle, Ronda; Triozzi, Pierre L.; LoBuglio, Albert F.; Wang, Wen-Quan; Fujimori, Matt; Conry, Robert M. A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma. Cancer Biotherapy & Radiopharmaceuticals. 2006-12, 21 (6) [2024-03-06]. ISSN 1084-9785. PMID 17257071. doi:10.1089/cbr.2006.21.561. （原始內容存檔於2024-06-04）.
- ^ Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma - Full Text View - ClinicalTrials.gov. clinicaltrials.gov. [2024-03-06]. （原始內容存檔於2021-04-10） （英語）.
- ^ Tarhini, Ahmad A.; Moschos, Stergios J.; Lin, Yan; Lin, Hui-Min; Sander, Cindy; Yin, Yan; Venhaus, Ralph; Gajewski, Thomas F.; Kirkwood, John M. Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma. Melanoma Research. 2017-08, 27 (4) [2024-03-06]. ISSN 1473-5636. PMID 28489678. doi:10.1097/CMR.0000000000000353. （原始內容存檔於2024-06-03）.
- ^ Adis insight: Ecromeximab. [2024-03-06]. （原始內容存檔於2017-01-03）.